The Relevance between Fecal Tumor M2 Pyruvate Kinase and Colonoscopy for the Detection of Cancer Colon

Background: Colorectal cancer (CRC) determination is focused on clinical, serological and endoscopic observations These methods are considered as non-invasive, cost-effective and convenient clinical examination methods. A direct association between M2 Pyruvate Kinase (M2-PK) and separate oncoprotein is the product of dissociation of tetrameric form from dimeric structure in tumor cells. The aim of this analysis is to assess the sensitivity in high risk or symptomatic populations of fecal tumor M2-PK.

Methods: This study is a cross sectional study carried out on 50 patients who were categorized into two groups: 25 patients with colorectal neoplasms (group 1). 25 patients symptomatizing of: diarrhea, persistent abdominal discomfort or bleeding per rectum, without colorectal neoplasms (group 2).

Results: The median value of stool M2-PK showed statistically significance. At cut-off ≥ 70 of stool M2-PK to predict activity, sensitivity was 88%, specificity was 84%, PPV was 84.6% and NPV was 87.5%. AUC was 0.907 and P value was <0.001.

Conclusions: Fecal M2-PK can be used as a pre colonoscopy screening test for CRC patients and is superior to other tumor markers (CEA and CA19.9) as it is more sensitive and specific. As a result of its low cost and ease of use, it is a viable tool for pre-selecting individuals who undergo colonoscopy.